CombiMatrix Corporation to Release Third Quarter and Nine-Month Financial Results on November 7, 2012

CombiMatrix Corporation to Release Third Quarter and Nine-Month Financial
Results on November 7, 2012

IRVINE, Calif., Oct. 31, 2012 (GLOBE NEWSWIRE) -- CombiMatrix Corporation
(Nasdaq:CBMX) announced today that it will release its third quarter and
nine-month 2012 financial results on Wednesday, November 7, 2012. Results will
be released prior to trading on that day.

A conference call has also been scheduled regarding CombiMatrix Corporation's
third quarter and nine-month 2012 financial results. The presentation and Q&A
session will start at 8:00 a.m. Pacific Time (11:00 a.m. Eastern) on November
7, 2012.

To attend the presentation by phone, dial 1-888-417-8516 for domestic callers
and 1-719-457-2083 for direct-dial or international callers. To listen to the
call via CombiMatrix's website, go to www.combimatrix.com in the
Investor/Events section (http://investor.combimatrix.com/events.cfm).

A replay of the presentation will be available following the presentation,
either via the CombiMatrix website Investor/Events section
(http://investor.combimatrix.com/events.cfm) or by dialing 1-877-870-5176 for
domestic callers or 1-858-384-5517 for direct-dial international callers. When
prompted, enter playback pin number 2492250.

About CombiMatrix Corporation

CombiMatrix Corporation, through its wholly owned subsidiary, CombiMatrix
Molecular Diagnostics, Inc. (CMDX), is a molecular diagnostics laboratory
which offers DNA-based testing services to the prenatal, pediatric and
oncology markets. The Company performs genetic testing utilizing Microarray,
FISH, PCR and G-Band Chromosome Analysis. CMDX offers prenatal and pediatric
testing services for the detection of abnormalities of genes at the DNA level
beyond what can be identified through traditional technologies. CMDX was also
the first commercial clinical laboratory in the United States to make
comprehensive DNA-based genomic analysis of solid tumors, including breast,
colon, lung, prostate and brain tumors, available to oncology patients and
medical professionals. Additional information about CMDX is available at
www.cmdiagnostics.com or by calling 1-800-710-0624.

CONTACT: Company Contact:
         R. Judd Jessup
         President & CEO, CombiMatrix Corporation
         Tel (949) 753-0624

         Investor Relations Contact:
         Matthew H. Clawson
         Partner, Allen & Caron Inc
         Tel (949) 474-4300
         matt@allencaron.com
 
Press spacebar to pause and continue. Press esc to stop.